Oral delivery of gastro-resistant microencapsulated typhoid vaccine

Journal of Drug Targeting

Volumn 17, Issue 7, 2009, Pages 553-560

  Uddin, Akm N ^a   Bejugam, Naveen K ^b   Gayakwad, Sanjay G ^c   Akther, Parvin ^d   D'Souza, Martin J ^e  

^a Barr Pharmaceuticals   (United States)

^b SRI INTERNATIONAL   (United States)

^c Azopharma Contract Pharmaceutical Services   (United States)

^d Sandoz Inc   (United States)

^e MERCER UNIVERSITY   (United States)

Author keywords

Albumin; Chitosan; Microspheres; Oral vaccine; Spray drying; Typhoid Vi antigen

Indexed keywords

ALBUMIN; CHITOSAN; GELATIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; MICROSPHERE; TYPHOID VACCINE; BACTERIAL POLYSACCHARIDE; BOVINE SERUM ALBUMIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; TYPHOID PARATYPHOID VACCINE; VI ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; DRUG CAPSULE; DRUG RESPONSE; MICROENCAPSULATION; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SPRAY DRYING; ZETA POTENTIAL; ANIMAL; CATTLE; CHEMISTRY; COMPARATIVE STUDY; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MICROCAPSULE; MOUTH MUCOSA; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; CAPSULES; CATTLE; CHITOSAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; MOUTH MUCOSA; PARTICLE SIZE; POLYSACCHARIDES, BACTERIAL; RATS; RATS, SPRAGUE-DAWLEY; SERUM ALBUMIN, BOVINE; TYPHOID-PARATYPHOID VACCINES;

EID: 70349787126     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903067301     Document Type: Article

References (46)

1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. (2002). Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release, 79(1-3), 29-40.
2. Allaoui-Attarki K, Pecquet S, Fattal E, Trolle S, Chachaty E, Couvreur P, Andremont A. (1997). Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect Immun, 65(3), 853-857.
3. Barrett TJ, Blake PA, Brown SL, Hoffman K, Llort JM, Feeley JC. (1983). Enzyme-linked immunosorbent assay for detection of human antibodies to Salmonella typhi Vi antigen. J Clin Microbiol, 17(4), 625-627.
4. Bejugam NK, Uddin AN, Gayakwad SG, D'Souza MJ. (2008). Formulation and evaluation of albumin microspheres and its enteric coating using a spray-dryer. J Microencapsul, 25(8), 577-583.
5. Carr KE, Hazzard RA, Reid S, Hodges GM. (1996). The effect of size on uptake of orally administered latex microparticles in the small intestine and transport to mesenteric lymph nodes. Pharm Res, 13(8), 1205-1209.
6. CDC. (1992). Health Information for International Travel. Atlanta: U.S. Department of Health and Human Services, Public Health Service.
7. Challacombe SJ, Rahman D, O'Hagan DT. (1997). Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. Vaccine, 15(2), 169-175.
8. Cheng G, An F, Zou MJ, Sun J, Hao XH, He YX. (2004). Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid. World J Gastroenterol, 10(12), 1769-1774.
9. Cole ET, Scott RA, Connor AL, Wilding IR, Petereit HU, Schminke C, Beckert T, Cadé D. (2002). Enteric coated HPMC capsules designed to achieve intestinal targeting. Int J Pharm, 231(1), 83-95.
10. Cripps AW, Kyd JM, Foxwell AR. (2001). Vaccines and mucosal immunisation. Vaccine, 19(17-19), 2513-2515.
11. Cumberland NS, St Clair Roberts J, Arnold WS, Patel RK, Bowker CH. (1992). Typhoid Vi: a less reactogenic vaccine. J Int Med Res, 20(3), 247-253.
12. Davis SS, Hardy JG, Fara JW. (1986). Transit of pharmaceutical dosage forms through the small intestine. Gut, 27(8), 886-892.
13. Degussa. (2003). Enteric Coatings-pH Control with EUDRAGIT. (p. 8). Rohm Pharma Polymers.
14. Degussa. (2005). Enteric coating of hard gelatin capsules with EUDRAGIT®3.3.4e Page 1-3. Pharma Polymers.
15. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tic TR. (1990). Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Control Release, 11(1-3), 205-214.
16. Eldridge JH, Staas JK, Meulbroek JA, McGhee JR, Tice TR, Gilley RM. (1991). Biodegradable microspheres as a vaccine delivery system. Mol Immunol, 28(3), 287-294.
17. Fegely KA, Simon BH, Rajabi-Siahboomi AR. (2006). Aqueous Enteric Coating Application on Non-Banded Hard Gelatin Capsules [AAPS Annual Meeting]. San Antonio, TX: The AAPS Journal, Poster # 2847.
18. Ferry BL, Misbah SA, Stephens P, Sherrell Z, Lythgoe H, Bateman E, Banner C, Jones J, Groome N, Chapel HM. (2004). Development of an anti-Salmonella typhi Vi ELISA: assessment of immunocompetence in healthy donors. Clin Exp Immunol, 136(2), 297-303.
19. Flick-Smith HC, Eyles JE, Hebdon R, Waters EL, Beedham RJ, Stagg TJ, Miller J, Alpar HO, Baillie LWJ, Williamson ED. (2002). Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect Immun, 70(4), 2022-2088.
20. Galazka AM. (1993). Immunological basis for immunization. Module 1: General immunology. In Global Programme for Vaccines and Immunization EPoI (p. 13). Geneva: World Health Organization.
21. Galindo-Rodriguez SA, Allemann E, Fessi H, Doelker E. (2005). Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst, 22(5), 419-464.
22. Handler ES, Varsa EE, Gordon AS. (1966). Mechanisms of leukocyte production and release. V. Studies on the leukocytosis-inducing factor in the plasma of rats treated with typhoid-paratyphoid vaccine. J Lab Clin Med, 67(3), 398-410.
23. Harvard-Apparatus. Mini Gelatin Drug Delivery Capsule. Last accessed May 23, 2008, at http://www.harvardapparatus.com/wcsstore/ ConsumerDirect/images/ site/hai/techdocs/BS4-B-42.pdf Last accessed 25 May 2008
24. Henriksen I, Green KL, Smart JD, Smistad G, Karlsen J. (1996). Bioadhesion of hydrated chitosans: an in vitro and in vivo study. Int J Pharm, 145(1-2), 231-240.
25. Jones BE. (2009). Enteric coating of hard capsules, part 1. Tablets & Capsules, 10-14.
26. Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. (1994). Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine, 12(3), 195-199.
27. Kramer PA. (1974). Letter: albumin microspheres as vehicles for achieving specificity in drug delivery. J Pharm Sci, 63(10), 1646-1647.
28. Kreuter J. (1996). Nanoparticles and microparticles for drug and vaccine delivery. J Anat, 189(Pt 3), 503-505. (Pubitemid 27011002)
29. Kyd J, Cripps A. (2000). Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. J Biotechnol, 83(1-2), 85-90.
30. Modi P, inventor, assignee. (1998). Drugs, Vaccines and Hormones in Polylactide Coated Microspheres. Canada. International publication # WO 95/22318 and International application # PCT/ CA95/00074.
31. O'Hagan DT. (1996). The intestinal uptake of particles and the implications for drug and antigen delivery. J Anat, 189(Pt 3), 477-482.
32. O'Hagan DT, McGee JP, Holmgren J, Mowat AM, Donachie AM, Mills KH, Gaisford W, Rahman D, Challacombe SJ. (1993). Biodegradable microparticles for oral immunization. Vaccine, 11(2), 149-154.
33. Park JH, Hong JJ, Choi ES, Lee JW. (2002). Efficacy of purified Vi polysaccharide typhoid vaccine. J Vet Sci, 3(2), 67-70.
34. Pina ME, Sousa AT, Brojo AP. (1996). Enteric coating of hard gelatin capsules. Part 1. Application of hydroalcoholic solutions of formaldehyde in preparation of gastro-resistant capsules. Int J Pharma, 133(1-2), 139-148.
35. Pina ME, Sousa AT, Brojo AP. (1997). Enteric coating of hard gelatin capsules. Part 2-bioavailability of formaldehyde treated capsules. Int J Pharma, 148(1), 73-84.
36. Poskitt DC, Duffey K, Barnett J, Kimpton WG, Muller HK. (1984). The gut-associated lymphoid system of two species of Australian marsupial mice, Antechinus swainsonii and Antechinus stuartii. Distribution, frequency and structure of Peyer's patches and lymphoid follicles in the small and large intestine. Aust J Exp Biol Med Sci, 62(Pt 1), 81-88.
37. Seong SY, Cho NH, Kwon IC, Jeong SY. (1999). Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun, 67(7), 3587-3592.
38. Szu SC, Stone AL, Robbins JD, Schneerson R, Robbins JB. (1987). Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals. J Exp Med, 166(5), 1510-1524.
39. Tabata Y, Inoue Y, Ikada Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14(17-18), 1677-1685.
40. Takeuchi H, Yamamoto H, Niwa T, Hino T, Kawashima Y. (1996). Enteral absorption of insulin in rats from mucoadhesive chitosan- coated liposomes. Pharm Res, 13(6), 896-901.
41. Typhim Vi®. (2005). Typhoid Vi Polysaccharide Vaccine (Typhim Vi®). Last accessed February 28, 2009, at http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM142811
42. van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. (2001). Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials, 22(7), 687-694. (Pubitemid 32112293)
43. Vivotif®. (2006). Typhoid Vaccine Live Oral Ty21a (Vivotif®). Last accessed February 28, 2009, at http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/ UCM142807
44. Walker RI. (1994). New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine, 12(5), 387-400.
45. WHO. (2003). WHO Background Document: The Diagnosis, Treatment and Prevention of Typhoid Fever. Geneva: Switzerland.
46. Yeboah KG, D'Souza MJ. (2009). Evaluation of albumin microspheres as oral delivery system for Mycobacterium tuberculosis vaccines. J Microencapsul, 26(2), 166-179.